抗凝固薬の世界市場動向：競争状況、パイプライン分析、市場規模予測...市場調査レポートについてご紹介

Introduction2

Executive Summary7

Blood Coagulation8
Antithrombotic Drugs9
Antiplatelets10
Fibrinolytic Drugs10

Anticoagulants11
Classification of Anticoagulants on the basis of agents11
Active Therapy Areas for Anticoagulants13
Marketed Drugs for Anticoagulants16
List of Marketed drugs with Indication and Approval date17
List of marketed drugs along with Dosage Form and Strength18
Type of Marketed Anticoagulants19
Marketed Anticoagulants Patent Details21
Withdrawal and Discontinued Drugs22
Marketed anticoagulants for each Indication23

Commercial Assessment26
Sales of Major players in Market26
Forecasted Sales of Major players in Market27
Pipeline Drugs for Anticoagulants28
Clinical profile of Phase III pipeline molecules28

Pipeline drugs by Phases30
Pipeline drugs by Mechanism of Action31
Pipeline drugs by Route of Administration32
Pipeline drugs by Molecule Type33
Profile of Pipeline Drugs34
Phase III/ Late Stage Molecules34
Phase II/ Mid Stage Molecules39
Phase I/Early Stage Molecules49
Pre-Clinical Stage Profiles54
Antidotes for Anticoagulants:57
Prevalent Indications for Anticoagulants58
Venous Thromboembolism58
Epidemiology of Venous Thromboembolism58
Trends in epidemiology59
Complications59
Diagnosis of Venous Thromboembolism60
Pathophysiology of Venous Thromboembolism61
Current and future market of Venous Thromboembolism61
Competition and Unmet Need of Venous Thromboembolism market62
Atrial Fibrillation63
Epidemiology of Atrial Fibrillation (AF)63
Diagnosis of Atrial Fibrillation (AF)64
Complications64
Treatment for Atrial Fibrillation65
Prescribing of anticoagulation treatment for atrial Fibrillation in England66
Current and Future Market of Atrial Fibrillation66
Annual cost of treatment for Atrial Fibrillation66
Future Treatment for Atrial Fibrillation67
SWOT Analysis68

Market Research Methodology69
Research Design69
Contact Us71
Disclaimer71

[List of Tables]
Table 1: Marketed Anticoagulants with Indication and approval date, 2015 17
Table 2: Marketed Anticoagulants with dosage Form and Strength, 2015 18
Table 3: Type of Marketed Anticoagulant drugs , 2015 19
Table 4: Marketed Anticoagulants, Patent Expiry Timeline, 2015 21
Table 5: Withdrawal and Discontinued Drugs, 2015 22
Table 6: Indication wise number of marketed drugs, 2015 23
Table 7: Characteristic of new oral anticoagulants compared with warfarin 24
Table 8: Comparative pharmacology of Warfarin with other drugs 24
Table 9: Choice of anticoagulant based on patient characteristics 24
Table 10: Sales of major players in Market, 2015 26
Table 11: Forecasted Sales of major players in Market, 2015 27
Table 12: Pipeline Anticoagulants, 2015 29
Table 13: Number of Assets in each phase of pipeline, 2015 30
Table 14: Number of pipeline drugs by Mechanism of Action, 2015 31
Table 15: Number of pipeline drugs by Route of Administration, 2015 32
Table 16: Number of pipeline drugs by Molecule Type, 2015 33
Table 17: Current Prescribing of anticoagulation treatment for Atrial Fibrillation in England 66
Table 18: Annual cost of treatment for Atrial Fibrillation 66
Table 19: Future Treatment for Atrial Fibrillation 67

[List of Figures]
Figure 1: Marketed Anticoagulants, Patent Expiry Timeline, 2015 21
Figure 2: Indication wise number of marketed drugs, 2015 23
Figure 3: Sales of major players in Market, 2015 26
Figure 4: Forecasted Sales of Major players in Market, 2015 27
Figure 5: Number of Assets in each phase of pipeline (%), 2015 30
Figure 6: Number of pipeline drugs by Mechanism of Action (%), 2015 31
Figure 7: Number of pipeline drugs by Route of Administration (%), 2015 32
Figure 8: Number of pipeline drugs by Molecule Type (%), 2015 33